Genetic disorders that lead to progressive muscle degeneration can have severe health consequences for patients, yet there is an unmet need for appropriate methods to monitor disease status. This pilot study demonstrates MSOT as a potential new clinical diagnostic for quantitative, robust assessment of muscle degeneration in Pompe disease.
